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Introduction
Estrogen receptor beta (ERβ) was first discovered in the rat prostate (Kuiper et al., 1996) . Since then, there has been considerable interest in understanding its role in both breast and prostate cancer. Despite a large body of literature, the function of ERβ in these two cancers remains unclear (Haldosen et al., 2014 , Nelson et al., 2014 . Prostate Cancer (CRPC) where it has been proposed as a driver of androgen receptor (AR)-dependent gene transcription (Yang et al., 2012 , Yang et al., 2015 , along with a potential role in mediating the transition from hormone-sensitive to CRPC (Zellweger et al., 2013) . In breast cancer, it has been suggested that ERβ may have a 'bi-faceted role' and should not simply be considered a tumor-suppressor (Jonsson et al., 2014) . ERβ has been reported to 'cross-talk' with androgen receptor-positive breast cancer (Rizza et al., 2014) In light of this, we sought to test and validate six commonly used, commercially available ERβ antibodies and two non-commercially available ERβ antibodies (Choi et al., 2001 , Wu et al., 2012 in a systematic manner that addresses these assumptions.
To achieve this, we employed a number of assays for antibody validation, including a novel proteomic-based pull down method called Rapid Immunopreciptation Mass spectrometry of Endogenous protein (RIME) (Mohammed et al., 2013) . We then applied successfully validated antibodies to cell line models of breast and prostate cancer commonly used for studies of ERβ to assess them for ERβ expression. ERβ expression in the cell lines was validated by a non-antibody dependent, targeted proteomics method known as Parallel Reaction Monitoring (PRM) (Gallien et al., 2012) . Finally, benign and malignant prostate and breast tissues were stained with the validated ERβ antibody to assess tissue expression of ERβ by IHC.
Materials and methods

Cell culture
The cancer cell line MDA-MB-231 with doxycycline-inducible ERβ expression (MDA-MB-231-ERβ) (Reese et al., 2014) was cultured in Dulbeccos Modified Eagle Medium with F12 supplement (DMEM/F12) with 10% heat-inactivated tetracyclinefree fetal bovine serum (FBS) (Fisher-Scientific), 2mM L-glutamine, 50 U/ml M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 penicillin, 50 µg/ml streptomycin, 5 µg/ml blasticidin S (Invivogen) to select for the tetracycline repressor and 500 µg/ml zeocin (Invitrogen) to select for the ERβ expression vector. To induce ERβ expression in MDA-MB 231-ERβ cells, 15 cm 2 plates were seeded with 5x10 6 cells and doxycycline added at either 0.1 µg/ml (for Western blot, real-time polymerase chain reaction (qRT-PCR) and PRM) or 0.5 µg/ml (for RIME) for 24 hours. The MCF-7 breast cancer cell line was cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated FBS (Fisher-Scientific), 2mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin.
The LNCaP prostate cancer cell line was cultured in RPMI 1640 with 10% heatinactivated FBS (Fisher-Scientific), 2mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. All cells were incubated at 37°C with 5% CO2 and cultured to 80 to 90% confluence. LNCaP and MCF-7 cell lines were obtained from ATCC (Middlesex, UK) and validated by STR genotyping.
Preparation of mRNA and qRT-PCR
MDA-MB-231-ERβ+, MDA-MB-231-ERβ-, MCF-7 and LNCaP cells were harvested for collection of mRNA using the RNEasy Mini Kit (Qiagen, California USA). On-column DNase digestion was performed to remove contaminating genomic DNA. RNA was quantified with the NanoDrop 8000 (Thermo Scientific, Delaware USA). Samples containing 250 ng random primers, 1 µg RNA, 1 µl 10mM dNTP mix and water to a total volume of 13 µl were heated to 65°C for 5 minutes, followed by 1 minute incubation on ice. To each sample 4 µl 5X First-strand buffer, 1 µl 0.1M DTT, 1 µl RNaseOUT and 1 µl SuperScript III reverse transcriptase (RT) (Thermofisher Scientific, Leicestershire, UK) were added and incubated at 25°C for 5 minutes then 50°C for 60 minutes followed by heating at 70°C for 15 minutes. qRT-PCR primers M A N U S C R I P T A C C E P T E D RealTime machine in triplicate. Hot-start Taq polymerase was heat-activated at 95°C for 10 minutes followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C.
Fluorescence was read in each cycle and a melting curve constructed as the temperature was increased from 65°C to 95°C with continuous fluorescence readings.
UBC was used as a control gene to normalize between the samples and relative expression determined using the delta-delta Ct method (Livak and Schmittgen, 2001 ).
Western blotting
MDA-MB-231-ERβ+, MDA-MB-231-ERβ-, MCF-7 and LNCaP cells were harvested for nuclear extract using the Ne-Per nuclear extraction kit (Thermo Scientific Pierce, Rockford IL USA) according to the manufacturer's instructions. Membranes were imaged using the Li-Cor Odyssey fluorescent imaging system (LI-COR Biosciences, USA).
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded MDA-MB-231-ERβ-and MDA-MB-231-ERβ+ cell pellets were generated, with ~2 x 10 7 cells per pellet. ERβ expression was induced with 0.5 µg/ml doxycycline for 24 hours. and species-specific IgG used to detect non-specific pull-down (Mouse sc2025 or 
Parallel Reaction monitoring (PRM).
Nuclear 
Statistics
Differences in ERβ mRNA levels observed in MDA-MB-231-ERβ-and MDA-MB-231-ERβ+ conditions were analyzed using unpaired t-tests. Differences were considered statistically significant at p = <0.05. Data presented are mean of technical triplicate experiments +/-standard deviation. Analysis was performed in GraphPad Prism version 6.
Results
ERβ Antibody Validation
Given the confusion in the ERβ field and the concern associated with variable and potentially non-specific reagents, we sought to extensively validate commonly used ERβ antibodies in a systematic manner that does not rely upon a priori assumptions regarding ERβ expression in cell line models or in tissues. As a control, we employed a cell line system with doxycycline-inducible expression of the ERβ protein, allowing us to assess antibodies in ERβ negative and matched ERβ positive conditions ( Fig. 2) , showing differential nuclear staining between the two conditions. The 8 ERβ antibodies were then assessed by an independent method called RIME, which uses an antibody-based purification followed by mass spectrometry (MS) to identify enriched peptides. We conducted RIME in MDA-MB-231-ERβ-and MDA-MB-231-ERβ+ cells using all 8 antibodies. E2F1 antibody was included in parallel as a positive control since E2F1 is a ubiquitous protein (Fig. 3A) and an IgG was used as a negative control (Fig. 3C) . In MDA-MB-231-ERβ-cells, no ERβ peptides were purified by any of the ERβ antibodies, confirming the ERβ negative status of the uninduced MDA-MB-231-ERβ cell line (Fig. 3C) . Following ERβ induction, RIME revealed diverse coverage of the ERβ protein by the different antibodies. The percent coverage of the ERβ protein following purification with each of the ERβ antibodies, and the location of the peptide fragments identified by MS are shown in Figure 3B .
To provide an indication of the specificity of each antibody, we ranked all the proteins purified by the IP and identified by MS according to the number of unique peptides (confirmed with a false discovery rate (FDR) of <1%). We hypothesized that the higher the ranking of ERβ, the greater the specificity of the antibody. Hence, if ERβ has the greatest number of unique peptides relative to all other proteins, it is ranked 1 st .
NCL-ER-BETA did not purify any ERβ peptides (Fig. 3B) , which is consistent with the lack of specificity identified from the Western blot result (Fig. 1C) . The Millipore 06-629 antibody positively pulled down ERβ in the test condition, although coverage and ranking were not as favorable as compared with some of the other antibodies.
Interestingly, LACTB, a 60 kDa protein was purified by Millipore 06-629 in both ERβ+ and ERβ-conditions (data not shown), which may explain the ~60 kDa band M A N U S C R I P T (Fig. 1) , the MC10 antibody was carried forward into the RIME experiments for the cell line characterization. The CWK-F12 antibody had 17.7% coverage, with ERβ ranking 2 nd in the list of purified peptides. As the
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CWK-F12 antibody produced very clean results by Western blotting, IHC and ranked
ERβ second in the list of purified proteins, it was used for Western blotting in the cell line characterization and directly compared against the non-specific NCL-ER-BETA antibody. The goal was to use independent validated ERβ antibodies and additional independent methods to assess whether the most commonly studied breast and prostate cancer cell line models express ERβ. (Fig. 4B) .
Characterization of LNCaP and MCF-7 cell lines for ERβ expression.
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Importantly, this demonstrates that the NCL-ER-BETA antibody is not detecting ERβ in either LNCaP or MCF-7 cancer cell line models and is instead identifying a nonspecific protein of similar molecular weight.
Furthermore, RIME analysis of LNCaP and MCF-7 cells using the validated MC10
ERβ antibody did not purify any ERβ peptides by MS (Fig. 4C ). This result was confirmed by an antibody-independent approach known as Parallel Reaction Monitoring (PRM), which demonstrated that no ERβ peptides were present in either of these cell lines (Fig. 4D ). As such, our early passage LNCaP and MCF-7 cell line M A N U S C R I P T
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20 models are ERβ negative and these cancer models should not be used for the analysis of this protein. (Fig. 1C and Fig. 3B ), but we have confirmed that this protein band is not ERβ through the use of the MDA-MB-231-ERβ inducible cell line system and the RIME technique. As such, this non-specific ~59 kDa band is likely to be the source of much of the controversy and confusion surrounding the study and characterization of ERβ. The PPG5/10
ERβ
antibody targets the C-terminus of wt ERβ, and as such may be useful for distinguishing wt ERβ from expression of ERβ isoforms. PPG5/10 identified ERβ in the MDA-MB-231-ERβ cell line by RIME, and has previously been shown to be ERβ-specific by IHC in both an inducible cell line model (Wu et al., 2012) and in breast tissue (Carder et al., 2005) . However, in our study this antibody did not show specificity by Western blot analysis (Fig 1C) . In their antibody validation study,
Carder et al. also assessed the Abcam 288[14C8] antibody and found it to be ERβ-specific for IHC in tissue (Carder et al., 2005) . Whilst our Western blotting data support this assertion (Fig. 1C) , our RIME data suggest that this antibody also purifies additional, non-specific peptides, and as such should be used with caution for IPbased methods (Fig 3B) . Taken together, these findings reassert the importance of validating antibodies for individual experimental approaches, rather than assuming M A N U S C R I P T
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23 general applicability across methodological platforms (Baker, 2015 , Bordeaux et al., 2010 . RIME was initially developed as a discovery tool to study the interacting proteomes of transcription factors in an unbiased manner (Mohammed et al., 2013) . The advantage of using RIME in antibody validation arises from being able to identify specific, named peptides purified by an antibody, rather than relying on the presence of a protein band of approximate size on a Western blot. This is typified by the NCL-ER-BETA antibody, which gave bands on Western blot in both ERβ-and ERβ+ conditions and no ERβ peptides identified by RIME. Taken together, these data confirm that this antibody is not specific to ERβ. The non-commercially available GeneTex 70182 detected ERβ, although there was non-specific signal at 65 kDa. Millipore 06-629 appears to detect ERβ, although there is also a 59 kDa band in the ERβ-condition. Review of the RIME data suggests this may be cross-reactivity with LACTB. NCL-ER-BETA, the most commonly used ERβ antibody, gives bands of the correct size for ERβ, but there is no difference between ERβ-and ERβ+ conditions, confirming that this antibody is not specific to ERβ. 
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